Jane C. Davies - Concepedia

Author

Jane C. Davies

Also Known As

Benjamin Montesinos, D Penelope, Damian Downey, Davies, J, Davies, J. C., Davies, JC, Davies, Jane, Davies, Jane C, Davies, Jane C., J C Davies

760

Publications

23.1K

Citations

H-Index

207

Concepts

All Affiliations

Imperial College London Royal Brompton Hospital Royal Brompton & Harefield NHS Foundation Trust Vertex Pharmaceuticals (United States)Cystic Fibrosis Trust

About

Jane C. Davies is an author at Imperial College London specializing in medicine, pulmonary fibrosis, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	75	4.9K
2	Health Sciences	7	7	249
3	Engineering	4	4	330
4	Education	1	1	27
5	Natural Sciences	1	1	125

Jane C. Davies

158

Publications

17.1K

Citations

H-Index

Page 1

	Year	Citations
A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney, New England Journal of Medicine	2011	2.1K
Disordered Microbial Communities in Asthmatic Airways Markus Hilty, Conor M. Burke, Helder Pedro, PLoS ONE	2010	1.8K
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i> Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey, New England Journal of Medicine	2015	1.6K
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	516
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation Jane C. Davies, Claire Wainwright, Gerard J. Canny, American Journal of Respiratory and Critical Care Medicine	2013	499
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis Steven M. Rowe, Cori Daines, Felix C. Ringshausen, New England Journal of Medicine	2017	499
Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial M. Stern, R Farley, Adam Jaffé, The Lancet FibrosisAllergyImmunologyPathologyPulmonary Pharmacology	1999	429
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial Eric W.F.W. Alton, David K Armstrong, Deborah Ashby, The Lancet Respiratory Medicine	2015	417
Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane Akshay Sabnis, Katheryn LH Hagart, Anna Klöckner, eLife	2021	369
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study Jane C. Davies, Steve Cunningham, William T. Harris, The Lancet Respiratory Medicine Single-arm StudyPathologyPulmonary FibrosisMedicineCftr Gating Mutation	2016	339

Page 1